Moirai Biodesign

Executive Summary

Moirai Biodesign is a Barcelona-based biotechnology company founded in 2021 that leverages computational RNA design to develop innovative diagnostics and therapeutics. The company's core technology employs AI-based algorithms to design a diverse range of RNA molecules, including ribozymes and long mRNAs, enabling programmable molecular sensors for RNA detection in various settings. With a focus on addressing challenges in diagnostics, Moirai Biodesign aims to provide rapid, sensitive, and specific RNA detection solutions that could transform point-of-care testing and disease monitoring. While still in early stages with no disclosed funding or revenue, the company's unique computational platform positions it well in the growing RNA-based diagnostics market. The team's expertise in RNA design and AI positions them to potentially disrupt traditional diagnostic methods, particularly in infectious disease and oncology applications. However, as a private, early-stage startup without public milestones, execution risk remains high, and the company's path to commercialization is yet to be proven.

Upcoming Catalysts (preview)

• Q3 2026Series A Funding Announcement60% success
• Q4 2026Strategic Partnership with Diagnostic Company50% success
• Q2 2026Publication of Proof-of-Concept Data in Peer-Reviewed Journal70% success